IBRX261204C00009000
IBRX Dec 4 2026 9.00 Call
optionOPRA
InactiveOct 27, 2026
1.63USD+61.386%(+0.62)1Vol1OI
Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
9
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 9 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.30 | -60.00% | 408 | 1,148 |
| Nov 20, 2026 | 7d | $0.57 | -37.36% | 196 | 6,793 |
| Nov 27, 2026 | 14d | $0.85 | +7.59% | 7 | 105 |
| Dec 4, 2026 | 21d | $1.63 | +61.39% | 1 | 1 |
| Dec 11, 2026 | 28d | $1.04 | +0.00% | 11 | 31 |
| Dec 18, 2026 | 35d | $0.96 | -30.43% | 3 | 1,585 |
| Dec 24, 2026 | 41d | — | — | 0 | 4 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $1.25 | -21.38% | 319 | 7,082 |
| Mar 19, 2027 | 126d | $1.58 | -4.24% | 35 | 702 |
| Apr 16, 2027 | 154d | $1.60 | -8.57% | 1 | 67 |
| May 21, 2027 | 189d | $1.90 | -2.56% | 1 | 316 |
IBRX Nearby Strikes · Dec 4, 2026
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.